SCHEDULE: Armistice Capital Boosts FibroGen Stake to 9.35%

Armistice Capital, LLC and Steven Boyd have disclosed a 9.35% beneficial ownership stake in FibroGen Inc., holding 378,000 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 5 to Schedule 13G regarding their beneficial ownership in FibroGen Inc.
• The Reporting Persons beneficially own 378,000 shares of FibroGen Inc. common stock, representing 9.35% of the class.
• This ownership percentage is based on 4,043,899 shares outstanding as of September 30, 2025, as reported in FibroGen's 10-Q filed on November 10, 2025.
• Armistice Capital, LLC, an investment adviser, exercises shared voting and dispositive power over these securities through its role as investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these securities.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of FibroGen Inc., except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.35% stake by an institutional investor like Armistice Capital is generally viewed positively, as it suggests a belief in the company's value or future prospects. The statement that shares are held in the ordinary course of business, not for control, also adds a layer of stability.

Positives

• A significant stake by an institutional investor like Armistice Capital can signal confidence in FibroGen's long-term prospects or valuation.
• The filing indicates the shares are held in the ordinary course of business, suggesting a strategic investment rather than an activist play aimed at immediate control changes, which can provide stability.

Negatives

• The filing itself does not contain information that would typically be categorized as 'negatives' regarding the issuer's performance or outlook.

Risks

• The filing does not detail specific risks related to FibroGen Inc.'s operations or financial health, as it is an ownership disclosure.

Future Outlook

This filing is an ownership disclosure and does not contain forward-looking statements or guidance from FibroGen Inc. or the reporting persons regarding the company's future performance.

Industry Context

This filing reflects an institutional investor's position in a biotechnology or pharmaceutical company. Such disclosures are common and provide transparency into significant ownership stakes, which can sometimes precede increased investor engagement or signal a belief in the company's market potential within its sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake can influence investor sentiment and potentially the stock price, signaling confidence or attracting further institutional interest.
• Management: While the filing states no intent to influence control, a large shareholder may still engage with management on strategic matters, potentially impacting corporate direction.

Key Dates

Recommendation

The filing indicates a significant institutional investment in FibroGen Inc. by Armistice Capital, holding 9.35% of the common stock. This suggests a positive long-term view from a sophisticated investor. However, as this is purely an ownership disclosure and provides no new operational or financial performance data, a 'hold' recommendation is appropriate for existing investors to await further company-specific news or financial results. For new investors, it signals a company that has attracted institutional interest, warranting further due diligence.

Keywords

FibroGen Inc., Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake, SEC Filing